GSK137647A

GSK137647A
Identifiers
	IUPAC name 4-methoxy-N-(2,4,6-trimethylphenyl)benzenesulfonamide;
CAS Number	349085-82-1;
PubChem CID	743974;
ChemSpider	650481;
ChEMBL	ChEMBL3311308;
Chemical and physical data
Formula	C16H19NO3S
Molar mass	305.39 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=C(C(=C1)C)NS(=O)(=O)C2=CC=C(C=C2)OC)C;
	InChI InChI=1S/C16H19NO3S/c1-11-9-12(2)16(13(3)10-11)17-21(18,19)15-7-5-14(20-4)6-8-15/h5-10,17H,1-4H3; Key:FQUAFMNPXPXOJE-UHFFFAOYSA-N;

GSK137647A (also called GSK137647) is an experimental drug which acts as a highly selective and moderately potent agonist for the free fatty acid receptor FFAR4 (GPR120).^[1] It has antiinflammatory effects^[2] and has been used to research the role of FFAR4 in various processes such as diabetes,^[3]^[4] ulcerative colitis,^[5] maintenance of bone density,^[6] and cancer.^[7]

References

^ Sparks SM, Chen G, Collins JL, Danger D, Dock ST, Jayawickreme C, et al. (July 2014). "Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120)". Bioorganic & Medicinal Chemistry Letters. 24 (14): 3100–3103. doi:10.1016/j.bmcl.2014.05.012. PMID 24881566.
^ Moonwiriyakit A, Yimnual C, Noitem R, Dinsuwannakol S, Sontikun J, Kaewin S, et al. (December 2023). "GPR120/FFAR4 stimulation attenuates airway remodeling and suppresses IL-4- and IL-13-induced airway epithelial injury via inhibition of STAT6 and Akt". Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 168 115774. doi:10.1016/j.biopha.2023.115774. PMID 37924784.
^ Zhang D, So WY, Wang Y, Wu SY, Cheng Q, Leung PS (February 2017). "Insulinotropic effects of GPR120 agonists are altered in obese diabetic and obese non-diabetic states". Clinical Science. 131 (3). London, England: 247–260. doi:10.1042/CS20160545. PMID 27980130.
^ McCloskey AG, Miskelly MG, Flatt PR, McKillop AM (January 2020). "Pharmacological potential of novel agonists for FFAR4 on islet and enteroendocrine cell function and glucose homeostasis". European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences. 142 105104. doi:10.1016/j.ejps.2019.105104. PMID 31669388.
^ Zhang LS, Zhang ZS, Wu YZ, Guo B, Li J, Huang XQ, et al. (March 2024). "Activation of free fatty acid receptors, FFAR1 and FFAR4, ameliorates ulcerative colitis by promote fatty acid metabolism and mediate macrophage polarization". International Immunopharmacology. 130 111778. doi:10.1016/j.intimp.2024.111778. PMID 38432147.
^ Wang C, Liu Y, Pan Y, Jin H (March 2020). "Effect of GSK-137647A, the first non-carboxylic FFA4 agonist, on the osteogenic and adipogenic differentiation of bone mesenchymal stem cells in db/db mice". The Journal of Pharmacy and Pharmacology. 72 (3): 461–469. doi:10.1111/jphp.13217. PMID 31858612.
^ Binienda A, Owczarek K, Sałaga M, Fichna J (December 2024). "Synthetic free fatty acid receptor (FFAR) 2 agonist 4-CMTB and FFAR4 agonist GSK13764 inhibit colon cancer cell growth and migration and regulate FFARs expression in in vitro and in vivo models of colorectal cancer". Pharmacological Reports : PR. 76 (6): 1403–1414. doi:10.1007/s43440-024-00667-5. PMC 11582145. PMID 39432182.

[1] Sparks SM, Chen G, Collins JL, Danger D, Dock ST, Jayawickreme C, et al. (July 2014). "Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120)". Bioorganic & Medicinal Chemistry Letters. 24 (14): 3100–3103. doi:10.1016/j.bmcl.2014.05.012. PMID 24881566.

[2] Moonwiriyakit A, Yimnual C, Noitem R, Dinsuwannakol S, Sontikun J, Kaewin S, et al. (December 2023). "GPR120/FFAR4 stimulation attenuates airway remodeling and suppresses IL-4- and IL-13-induced airway epithelial injury via inhibition of STAT6 and Akt". Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 168 115774. doi:10.1016/j.biopha.2023.115774. PMID 37924784.

[3] Zhang D, So WY, Wang Y, Wu SY, Cheng Q, Leung PS (February 2017). "Insulinotropic effects of GPR120 agonists are altered in obese diabetic and obese non-diabetic states". Clinical Science. 131 (3). London, England: 247–260. doi:10.1042/CS20160545. PMID 27980130.

[4] McCloskey AG, Miskelly MG, Flatt PR, McKillop AM (January 2020). "Pharmacological potential of novel agonists for FFAR4 on islet and enteroendocrine cell function and glucose homeostasis". European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences. 142 105104. doi:10.1016/j.ejps.2019.105104. PMID 31669388.

[5] Zhang LS, Zhang ZS, Wu YZ, Guo B, Li J, Huang XQ, et al. (March 2024). "Activation of free fatty acid receptors, FFAR1 and FFAR4, ameliorates ulcerative colitis by promote fatty acid metabolism and mediate macrophage polarization". International Immunopharmacology. 130 111778. doi:10.1016/j.intimp.2024.111778. PMID 38432147.

[6] Wang C, Liu Y, Pan Y, Jin H (March 2020). "Effect of GSK-137647A, the first non-carboxylic FFA4 agonist, on the osteogenic and adipogenic differentiation of bone mesenchymal stem cells in db/db mice". The Journal of Pharmacy and Pharmacology. 72 (3): 461–469. doi:10.1111/jphp.13217. PMID 31858612.

[7] Binienda A, Owczarek K, Sałaga M, Fichna J (December 2024). "Synthetic free fatty acid receptor (FFAR) 2 agonist 4-CMTB and FFAR4 agonist GSK13764 inhibit colon cancer cell growth and migration and regulate FFARs expression in in vitro and in vivo models of colorectal cancer". Pharmacological Reports : PR. 76 (6): 1403–1414. doi:10.1007/s43440-024-00667-5. PMC 11582145. PMID 39432182.

[1]

[2]

[3]

[4]

[5]

[6]

[7]